# Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

Source: https://onco.cc/trials/nct07007780/  
OnCo record `nct07007780` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab tirumotecan in triple-negative breast cancer, run by Xijing Hospital, not yet recruiting.

## Summary

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC is a phase 2, interventional study registered as NCT07007780 by Xijing Hospital, with a registry enrolment figure of 35 participants, started 2025-08-20 and due to reach its primary completion in 2026-08-31. Interventions recorded: Sacituzumab Tirumotecan. Conditions listed: Triple -Negative Breast Cancer. Triple-negative eligibility wording from the registry: "TNBC Confirmation: Confirmed as TNBC based on histology and/or cytology, and meeting the following criteria:". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07007780
- Phase: 2
- Setting: A Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC
- Sponsor: Xijing Hospital
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT07007780: https://clinicaltrials.gov/study/NCT07007780

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07007780.json